41:I[185,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SendEmailButton"] 43:I[63625,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"AddToLibraryButton"] 44:I[29721,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ShareButton"] 45:I[58016,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"ProcessEpisodeButton"] 46:I[45269,["/_next/static/chunks/2ys9ev5m3_24i.js","/_next/static/chunks/3pomb8r7ja54n.js","/_next/static/chunks/42spz6paskvb6.js","/_next/static/chunks/178kgr5-cejk9.js","/_next/static/chunks/1v5ewlr55okcj.js","/_next/static/chunks/3jnlvw-emqotx.js"],"SignupCTA"] 3b:["$","div",null,{"className":"flex flex-wrap items-center gap-x-4 gap-y-1 font-mono text-[12px] uppercase tracking-[0.1em] text-[color:var(--fg-3)]","children":[["$","time",null,{"dateTime":"2026-03-19T08:00:00.000Z","children":"March 19, 2026"}],["$","span",null,{"aria-hidden":true,"children":"·"}],["$","span",null,{"children":"00:19:52"}],false]}] 42:T4c7,

In this special sponsored episode from Eli Lilly and Company, I am joined by Dr. Lee James, senior vice president of oncology medical affairs at Lilly, to discuss the importance of lung cancer screening, early detection, and advances in biomarker testing. We explore how low-dose CT screening can reduce mortality, yet remains underused, and why comprehensive genomic profiling is essential to understanding the molecular drivers of non-small cell lung cancer and guiding targeted treatment decisions. Tune in to learn how expanding access to screening and precision medicine is helping create new hope for people affected by lung cancer.

VISIT SPONSOR → https://www.lilly.com/conditions/cancer/lung-cancer

SUBSCRIBE TO THE PODCAST → https://www.kevinmd.com/podcast

RECOMMENDED BY KEVINMD → https://www.kevinmd.com/recommended